Free tool
FAERS Monitor: Fruzaqla
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 217564 or its brand name (Fruzaqla, Fruquintinib). Reports on generic versions are filed under their own applications.
Reports
3,941
Serious
3,790
96% of reports
Hospitalization
1,205
Death reported
1,270
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death861
- fatigue482
- colorectal cancer metastatic396
- colon cancer381
- diarrhoea289
- blood pressure increased272
- decreased appetite249
- asthenia246
- myelosuppression244
- dysphonia213
- hypertension199
- off label use190
- nausea189
- pain155
- palmar-plantar erythrodysaesthesia syndrome133
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2019 | 6 |
| 2020 | 11 |
| 2021 | 5 |
| 2022 | 17 |
| 2023 | 59 |
| 2024 | 1,193 |
| 2025 | 1,820 |
| 2026 | 830 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,218 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| colorectal cancer metastaticSignal | 396 | 1070.4 | 965.4 | 351,613 |
| colon cancerSignal | 381 | 140.0 | 127.1 | 51,139 |
| myelosuppressionSignal | 244 | 36.4 | 32.2 | 8,321 |
| palmar-plantar erythrodysaesthesia syndromeSignal | 133 | 30.6 | 25.9 | 3,763 |
| dysphoniaSignal | 213 | 19.5 | 17.1 | 3,717 |
| blood pressure increasedSignal | 272 | 9.5 | 8.5 | 2,074 |
| decreased appetiteSignal | 249 | 5.7 | 5.1 | 976 |
| deathSignal | 861 | 5.3 | 5.0 | 3,157 |
| hypertensionSignal | 199 | 5.0 | 4.4 | 642 |
| astheniaSignal | 246 | 3.5 | 3.1 | 443 |
| fatigueSignal | 482 | 3.3 | 3.0 | 802 |
| diarrhoeaSignal | 289 | 2.4 | 2.1 | 239 |
| pain | 155 | 1.3 | 1.2 | 14 |
| nausea | 189 | 1.3 | 1.1 | 11 |
| off label use | 190 | 1.2 | 1.0 | 4 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.